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Abstract
Background and purpose
Individualized therapy in endometrial cancer, the most common gynaecologic cancer in the
developed world, focuses on identifying specific molecular subtypes. Mutations in the exo-
nuclease domain of the DNA polymerase epsilon (POLE) gene define one such subtype,
which causes an ultra-mutated tumour phenotype. These tumours may have an improved
progression-free survival and may be receptive to specific therapies. However, the clinical
phenotype of these tumours is unknown. The objective of this study was to evaluate the clin-
ical and genetic features of POLE-mutated tumours from a large cohort of women whose
cases are characterized by: (1) the availability of detailed clinical and lifestyle data; (2) muta-
tion analysis; and (3) long-term follow-up.
Methods
A total of 604 patients with endometrial cancer were included in the study. Data from a
detailed questionnaire, including lifestyle and family history information, provided extensive
pertinent information on the patients. Sequencing of exons 9–14 of the POLE gene was per-
formed. Follow-up data were gathered and analysed.
Results
Hotspot pathogenic POLE mutations were identified in N = 38/599 patients (6.3%). Patients
with a POLE-mutated tumour were significantly younger, were more often nulliparous, and
had a history of smoking. POLE-mutated tumours were more frequently aneuploid. Progno-
sis for patients with hotspot POLE-mutated tumours was significantly better in comparison
with patients with non-mutated tumours; however careful selection of pathogenic mutations
is essential to the definition of this prognostically favourable group.
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Conclusions
This study demonstrates that POLE-mutated endometrial cancer is significantly associated
with previously unknown clinicopathologic characteristics. Outcome in POLE-mutated
tumours was excellent in cases with hotspot mutations. Our results suggest that prediction
of excellent outcome in cases of POLE-mutated EMCA should be restricted to cases of
EMCA with hotspot mutations until further data are available on the rising number of muta-
tions with unknown significance.
Introduction
Mutations in the exonuclease domain of the polymerase epsilon (POLE) gene are associated with
an ultra-mutated genetic phenotype, increased neoantigen load, increased tumour infiltrating
lymphocytes, and potential responsiveness to immune therapy [1–5]. POLE mutations have been
identified in 7–12% of endometrial cancers (EMCA), as well as in 1–2% of colorectal cancers,
and have been described in rare cases of breast, pancreatic, stomach, lung, ovarian, and brain
tumours [6]. These tumours show a better progression-free survival when compared to other
tumours of similar type, grade, and stage [7–11]. The importance of the POLE gene in DNA rep-
lication was initially described in 2007 in studies on yeast, which showed its function in removing
errors during leading-strand replication [12]. Mutations in this gene were first described in colo-
rectal cancer in 2012, and its importance has been described recently in EMCA [13,14]. The
defect in the exonuclease proofreading domain leads to an extremely high mutation load [5,15].
This, in turn, appears to lead to increased neoantigen production and activation of the patient’s
immune system. This association with increased tumour-infiltrating lymphocytes, mostly with
CD8 T-cells, may explain why these tumours appear to have an improved prognosis [1,4,16–18].
POLE mutations define a specific molecular subgroup of EMCA, with both therapeutic and
prognostic significance. Ultra-mutated tumours with POLE mutations were identified as one
of the four proposed molecular subgroups in a publication of The Cancer Genome Atlas
(TCGA) based on their integrated genomic, transcriptomic, and proteomic characterization of
373 cases of EMCA [19].
The clinical characteristics of patients whose tumours have a POLE mutation are not clear.
Several studies of EMCA cohorts have indicated that patients with POLE-mutated tumours
are younger. A large retrospective study in colorectal cancer demonstrated that POLE-mutated
tumours occur in younger patients more often than non-POLE-mutated tumours (median
54.5 years for POLE-mutated tumours vs. 67.2 years for non-POLE-mutated tumours). In that
particular study, tumours were identified primarily in men. Previous studies have also indi-
cated that women with POLE-mutated EMCA tend to have lower BMI. POLE-mutated
tumours are described as having excellent outcome, even in high-grade endometrioid histol-
ogy, usually known to be associated with a more aggressive tumour. Therefore, it has been pro-
posed that POLE-mutated tumours might need less aggressive treatment and, if they do need
treatment, they might be eligible for checkpoint inhibitors, due to the highly immunogenic
character of these tumours [3,20]. The role of other clinical factors of potential importance in
EMCA is unclear. In addition, the definition of pathogenic mutations used to classify a tumour
as “POLE mutated” is not yet clearly defined.
The goal of this study was to evaluate the clinical and genetic features of POLE-mutated
tumours from a large cohort of women whose cases are characterized by: (1) the availability of
detailed clinical and lifestyle data; (2) mutation analysis; and (3) long-term follow up.
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Materials and methods
Cohort description
The combined Karolinska-Bern cohort (KImBer, N = 604) includes patients diagnosed at the
Karolinska University Hospital (KS) and the University Hospital Bern (Bern). The KS patients
were enrolled prospectively in the International Endometrial Tumour Analysis (IETA) study
conducted between February 2011 and January 2016 for expert ultrasound assessment, after
the diagnosis of EMCA through biopsy, D&C, or hysteroscopic resection [21]. Median follow-
up period was 34 months (0–75 months). The cohort reflects the Stockholm population inas-
much as all patients with EMCA in the Stockholm region are treated at the KS. Responses to
an extensive patient questionnaire were obtained at the time of diagnosis. The Bern cohort was
gathered retrospectively, selected by the availability of tumour tissue after surgery from
patients with a diagnosis of EMCA who had consented between 2004 and 2015 to the use of
their tissue for research. The University Hospital of Bern is a tertiary referral clinical; the
patients in the cohort are therefore representative of high-risk tumours and/or high-risk
patients. Median follow-up time was 59.6 months (0–156 months). DNA isolation and tissue
microarray construction were the same for both cohorts.
Clinical and mutation analysis data
For the reporting of all methods and results, the REMARK guidelines were applied [22,23].
The clinical data, including preoperative patient characteristics, therapies, histology data, and
follow-up, were obtained from the respective hospital internal electronic databases. Addition-
ally, patients in the KS cohort were evaluated via a more detailed questionnaire, filled out in
discussion with one of the co-authors (EE). These parameters included information on per-
sonal cancer history (subdivided by type: ovarian cancer, breast cancer, colon cancer, and
other cancer), family history of cancer (ovarian cancer, breast cancer, colon cancer, and other
cancer), lifestyle (smoking, alcohol consumption, and exercise), body measurements (height,
weight, waist measurement, and bra cup size), and menstrual history. Risk classification was
applied following the ESMO-ESGO-ESTRO consensus [24].
For survival status, patients were categorized as “alive,” “death due to disease,” “death due
to other cause,” or “death of unknown cause.” Overall survival (OS) was calculated from date
of surgery until death from any cause or until the date of last follow-up. Disease-specific sur-
vival (DSS) was the time from surgery to death due to disease. Progression-free survival (PFS)
was the time from surgery to recurrence or progression (based on clinical evidence or diagno-
sis from imaging or biopsy).
The histopathological diagnoses were all reviewed by two experienced gynaecological
pathologists (JC and TR), and diagnoses were made as defined in the WHO 2014 classification
of EMCA. The following parameters were extracted from the pathology reports: microcystic,
elongated, and fragmented (MELF) patterns, present or not; depth of invasion; cervical inva-
sion; lymph vascular space invasion (LVSI); and ploidy.
For the identification of POLE mutations, genomic DNA was isolated from punches from
formalin-fixed paraffin-embedded tumour tissue after choosing a region with>60% tumour
and<20% necrosis. After quality control and purification (S1 File), bidirectional Sanger
sequencing was performed according to standard protocols, using M13-tailed primers on an
ABI 3500 Genetic Analyzer (Life Technologies, Carlsbad, CA, USA) and a BigDye Terminator
v3.1 Cycle Sequencing Kit (Life Technologies). Mutation analysis of exons 9–14 (in the Bern
cohort 9, 12, 13, and 14) was done using Mutation Surveyor software (SoftGenetics, State Col-
lege, PA, USA) as well as manual inspection. Non-synonymous mutations were confirmed by
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resequencing and, in the cases of mutations with unknown predicted pathogenicity, DNA
from normal tissue (for example, myometrium) was extracted and sequenced for the described
mutation in order to exclude germline variants. After confirming that mutations were somatic,
the pathogenic impact of the mutation was annotated in three groups: hotspot mutation
(P286R, V411L, S297F, A456P and S459F), POLE mutation with published high total muta-
tional burden (TMB) (TMB>100Mb) (in our cohort A465V, D462Y, P436H), POLE mutation
of unknown significance (VUS). For the subsequent analysis, except where specifically stated,
only the POLE hotspot mutations were defined as POLE mutated.
Research ethics approval was obtained by the Regional Ethical Review Board of Stockholm,
(reference number: 2011/34) and the Ethics Committee Bern, Switzerland (reference number:
2018–00479).
Statistical analysis
Demographic and clinical-pathologic characteristics are presented using basic descriptive
statistics. To further compare the characteristics of the two groups (POLE mutated and
non-POLE mutated), Fisher’s exact test and independent t-tests were used. For variables
not meeting the assumptions of the t-test equivalent, a non-parametric test was used. Sur-
vival analysis was performed by using Kaplan-Meier curves and with log rank test. For
assessing risk factors for recurrence (PFS) and for DSS, Cox regression analysis was per-
formed to evaluate the effect of all the different parameters (POLE mutation, histology,
age, Grade, FIGO, etc) on outcome. All analyses were performed using SPSS version 25.0
(IBM). All p values tests were two sided, and p values <0.05 were considered statistically
significant.
Results
Patient characteristics
A total of 604 patients were included in the study: 349 from the KS cohort and 255 from
the Bern cohort. In five patients, the DNA quality was insufficient for analysis of all exons,
and these patients were therefore excluded. Sanger sequencing was successful in all
tumours. A hotspot POLE mutation was identified in 38/599 patients (6.3%). Standard
patient characteristics, available for all 599 patients, are presented in Table 1. Patients
with POLE-mutated tumours were significantly younger at the time of diagnosis than
patients with non-POLE-mutated tumours (60.1 vs 66.5 years; p = 0.000). Additionally,
these patients were more often nulliparous (39.5% vs 22.6%; p = 0.028) and had a tendency
towards lower BMI, although this difference was not statistically significant. Detailed
patient characteristics and life-style information were available for most of the KS cohort
(N = 342 out of a total of 349). The significant data are summarized in Table 2. The data
show that patients with POLE-mutated tumours were significantly more often smokers or
ex-smokers (p = 0.041). A non-significant trend was seen in the use of hormone replace-
ment therapy (more frequent in non-POLE-mutated cases) and, interestingly, in cases
with a family history of colon cancer. Four out of the five patients with a POLE-mutated
EMCA and a family history of colon cancer showed a P286R mutation. None had a per-
sonal history of colon cancer and none showed micro-satellite instability.
Tumour histopathology
Histopathologic characteristics of the tumours are presented in Table 1. The POLE-mutated
tumours were mostly, but not exclusively, endometrioid and low risk. No significant
Phenotype of POLE-mutated endometrial cancer
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Table 1. Clinicopathological characteristics.
POLE mutated No POLE mutation p-value
N = 38 N = 561
Age at time of diagnosis (mean, range) 60,1 (41–80) 66,5 (31–93) 0,000
BMI (mean, range) 27,4 (20,4–41,5) 29,8 (16,4–58,6) 0,071
Parity
Nullipara 15 (39,5%) 126 (22,5%)
Multipara 23 (60,5%) 434 (77,5%) 0,028
Menopausal status
premenopausal 6 (15,8%) 48 (8,6%)
Postmenopausal 32 (84,2%) 513 (91,4%) 0,140
Histology
Endometrioid 31 (81,6%) 468 (83,4%)
Non-endometrioid 7 (18,4%) 93 (16,6%) 0,822
Grade
1,2 22 (57,9, 2%) 411 (73,3%)
3 16 (57,9%) 150 (26,7%) 0,059
FIGO
I 33 (86,8,2%) 414 (73,8%)
II 2 (5,3%) 53 (9,4%)
III 3 (7,9%) 67 (11,9%)
IV 0 (0%) 27 (4,8%) 0,282
Lymphadenectomy
LN positive 2 (8,7%) 61 (22%)
LN negative 21 (91,3%) 216 (78.0%) 0,183
No LND performed 16 (42,1%) 310 (55,6%) 0,130
Tumour size mm 32,06 34,03 0,482
Cervical invasion
None 35 (92,1) 440 (78,6%)
Mucosal 0 (0%) 29 (5,2%)
Stromal 3 (7,9%) 91 (16,3%) 0,113
Depth of invasion
Intramucosal 1 (2,6%) 52 (9,3%)
<50% 23 (60,5%) 286 (51,1%)
>50% 14 (36,8%) 222 (39,6%) 0,292
LVSI
Negative 23 (60,5%) 414 (73,8%)
Positive 15 (39,5%) 147 (26,2%) 0,075
Ploidity
Aneuploid 13 (48,1%) 90 (29,6%)
Diploid 14 (51,9%) 214 (70,4%) 0,046
ESMO Group
Low risk 14 (36,8%) 224 (39,9%)
Intermediate risk 1 (11,7%) 69 (12,3%)
High intermediate risk 9 (23,7%) 49 (8,7%)
High risk 14 (36,8%) 189 (33,7%)
Advanced/metastatic 0 (0%) 30 (5,3%) 0,010
Missing data: Parity N = 1, BMI N = 107, depth on invasion: N = 1, Tumour size: N = 55; cervical invasion = 1,
Ploidy only KS cohort (Data on 331 patients). Statistical analysis: numerical independent t-test, categorical Fisher’s
exact
https://doi.org/10.1371/journal.pone.0214318.t001
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differences between the two groups were found with regard to the histologic type or tumour
stage; the tumours have no clear defining histological phenotype. In numbers, there are more
FIGO Stage I (86.8% vs 73.8%) and Grade 3 tumours (57.9% vs 26.7%) but these findings were
not significant. In the POLE-mutated group, the non-endometrioid histologic types were four
mixed carcinomas, one serous carcinoma, and two clear-cell carcinomas. There were signifi-
cant differences among risk-group categories, notably with fewer advanced risk cases in the
POLE mutated group. Data on ploidy of the tumours were available for the KS cohort only; for
this cohort, the POLE-mutated tumours were significantly more often aneuploid.
POLE mutations
In the KS cohort, where exons 9–14 were sequenced, no POLE mutations were found on exon
10. Only one POLE mutation was found on exon 11, which was classified as a non-pathogenic
variant (ie VUS, not an ultramutated phenotype). Therefore, in the Bern cohort, only exons 9,
12, 13, and 14 were sequenced. The number of mutations found on each exon were: 31 on
exon 9; 1 on exon 12; 13 on exon 13; and 11 on exon 14.
Thirty-eight tumours had at least one hotspot POLE mutation (see Table 3). An additional
19 tumours had mutations that were classified as not defined as hotspot mutations for the pur-
poses of this study but have been previously described as having an ultramutated phenotype
(N = 3). Finally, a number of variants of unknown significance were identified: “variants of
unclear significance” with high pathogenic FATHMM predictive scores (N = 8), “variants of
unclear significance” without any available FATHMM predictive score (N = 7), or non-
Table 2. Detailed patient characteristics of POLE mutated tumours.
POLE mutated Non-POLE mutated (N = 306) p-value
(N = 36)
Smoking
Never 17 259
Ever or currently 11 55 p = 0,018
Family history of EMCA
(Number of relatives)
0 25 (89,3%) 285 (89,3%)
1 2 (7,1%) 25 (8,0%)
2 1 (3,6%) 3 (1%)
3 0 1 (0,3%) p = 0,655
Family History of colorectal cancer
(Number of relatives)
0 23 (82,1%) 294 (93,6%)
1 5 (17,9%) 17 (5,4%)
2 0 2 (0,6%)
3 0 1 (0,3%) p = 0,078
HRT yes 7 (25,0%) 77 (24,5%) p = 0,955
Bra cup
Small (0–3) 21 198
Large (4–8) 8 116 p = 0,162
Waist length (mean) 98,04cm 99,01 p = 0,161
Height (mean) 165,0cm 165, 0 p = 0,995
Data on 342 patients (most of the KS cohort, 7 missing data on IETA questionnaire). HRT: Hormone replacement
therapy. Statistical analysis: numerical independent t-test, categorical Fisher’s exact
https://doi.org/10.1371/journal.pone.0214318.t002
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pathogenic FATHMM score (N = 1). A subgroup analysis was performed looking at alternative
definitions of POLE mutated EMCA. In this analysis, defining POLE mutated EMCA as only
including hotspot mutations provided the best patient outcome. Including both hotspot and
ultramutated tumors also showed an good outcome, and the survival benefit was significant
(S2 File). Including hotspot, ultramutated, and “VUS with a pathogenic FATHMM score” in
the POLE EMCA resulted in no significant survival difference between the groups (S2 File).
For this purposes of all further discussion, POLE mutated EMCA included only hotspot muta-
tions. All other cases were thus excluded and placed into the non-POLE mutated group.
Table 3 shows the mutations found and the classification as hotspot, ultramutated, or VUS.
Clinical outcomes
As described previously, only hotspot mutations were included in the POLE mutation group
unless specifically mentioned. The non-POLE group includes all remaining cases unless
Table 3. POLE mutations and classification.
Nucleotide substitution Amino acid
chang
Exon Nr of mutations
found
Decision
pathogenic
FATHMM prediction
score
Hyper-mutated phenotype
described
Hotspot mutations
c.857C>G P286R 9 22 hotspot 1 yes
c.1231G>C V411L 13 9 hotspot 0.99 yes
c.1376C>T S459F 14 4 pathogenic 0.99 yes
c.1366G>C A456P 14 1 pathogenic 0.99 yes
c.890C>T S297F 10 1 pathogenic 0.99 yes
Ultramutated
c.1394C>T A465V 14 1 Pathol. phenotype 1 yes
c.1384G>T D462Y 14 1 Pathol. phenotype yes: 278.4
c.1307C>A P436H 13 1 Pathol. phenotype yes, 541.36
Unclear significance with high
prediction score
c.1231G>A V411M 13 3 VUS 0.99
c.1370C>T T457M 14 2 VUS 1
c.808G>A V270M 9 1 VUS 0.99
c.1175A>G D392G 12 1 VUS 0.99
c.885G>A M295I 9 1 VUS 0.99
c.901G>A D301N 9 1 VUS 0.99
c.1283C>T A428V 13 1 VUS 0.99
c.1439C>T A480V 14 1 VUS 0.99
Unclear significance
c.1240G>A D414N 13 1 VUS
c.1423C>T H475Y 14 1 VUS
c.887T>G I296S 9 1 VUS
c.1461G>A M487I 14 1 VUS
c.1190A>G Y397C 12 1 VUS
c.1103A>T D368V 11 1 VUS
c.844C>T P282S 9 1 VUS
Benign
c.1371G>A T457T 14 1 benign neutral score 0.04
FATHMM = Functional Analysis through Hidden Markov Models; VSCS = Variant of strong clinical significance (pathogenic); VUS = Variant of unknown significance
(non-pathogenic)
https://doi.org/10.1371/journal.pone.0214318.t003
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otherwise specified. In the outcome analysis, 1/38 (2.7%) patient with POLE mutations showed
recurrence, as compared to 89/526 (16.9%) in the non-POLE-mutated group (p = 0.023). One
patient with a hotspot POLE-mutated tumour lacked follow-up data and was excluded from
the recurrence analysis. Time to recurrence was 25 months for the patient with POLE muta-
tion and a mean of 18.1 months (SD 18.8) for the non-POLE-mutated group (p = 0.745). The
patient with recurrence had a serous histology with LVSI positive tumour, FIGO Stage 1, and
had an adjuvant chemotherapy. In the POLE-mutated group, 37 (97.4%) were alive at last fol-
low-up, and 1 (2.6%) died of disease. In the non-POLE-mutated group, 454 (81.7%) were alive,
56 (10.1%) died of disease, 15 (2.7%) died of unknown causes, 28 (5.0%) died of other causes,
and 3 (0.5%) died due to treatment (p = 0.181). Five patients were lost to follow-up. Overall
survival was 22.8 months (SD 14.09) and 26.2 months (SD 18.51) respectively (p = 0.645).
Mean follow-up time was 47.5 months (12–155) vs 46.8 months (0–156) (p = 0.710).
Comparison of survival of both groups is shown in Fig 1, with the Kaplan-Meier curves for
PFS, DSS, and OS. Patients with POLE-mutated tumours had a significantly better PFS and
OS (og-rank results of 0.025, 0.147, and 0.023 respectively). Furthermore, applying Cox regres-
sion for analysing the risk of POLE mutations shows a hazard ratio for recurrence (PFS) of
Fig 1. Kaplan Meier analysis of POLE vs. non POLE-mutated tumours for PFS, DSS and OS. PFS: Progression free survival (operation to recurrence or
progression). DSS: Disease specific survival (operation to death due to disease). OS: Overall survival (operation to death of any cause). Red line: patients with
POLE-mutated tumour, censored. Blue line: patients with no POLE-mutated tumour, censored.
https://doi.org/10.1371/journal.pone.0214318.g001
Phenotype of POLE-mutated endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0214318 March 27, 2019 8 / 15
0.145 (CI 0.020–1.043, p = 0.055) and for DSS of 0.258 (CI 0.036–1.862, p = 0.179), both being
just non-significant.
In summary, the POLE-mutated tumour cases had a better outcome compared to the rest
of the cohort.
Analysis of the surgical and adjuvant treatments was performed in order to observe the
effect of treatment: hysterectomy (HE) with bilateral salpingo-oophorectomy (BSO) alone was
performed in 16 (42.1%) versus 310 (55.4%) cases; HE/BSO/pelvic lymphadenectomy (PLND)
was performed in 5 (13.2%) versus 85 (15.2%); and HE/BSO/PLND/Para-aortal lymphade-
nectomy (PALND) was performed in 17 (44.7%) vs 154 (27.5%) cases. In the non-POLE-
mutated group, 11 (2%) underwent other types of surgery (including intestinal surgery); infor-
mation was missing for one patient. In the POLE-mutated group, more LND were performed
(57.9% vs 44.4%); this finding was not significant (p = 0.107). Both clinics are dedicated to
minimally invasive surgery for EMCA; therefore, the surgery performed was minimally inva-
sive (laparoscopy or robotic surgery) in 77.4% vs 81.5% (p = 0.464) cases. Of the 273 patients
having at least a PLND, the mean number of lymph nodes removed was 32.9 vs 35.3
(p = 0.502); this shows that when a lymphadenectomy was performed, it was the same proce-
dure in both groups and sufficiently extensive.
Concerning adjuvant treatment, 22 (57.9%) vs 323 (58.9%) (p = 0.899) had no treatment at
all. Comparison of the different forms of adjuvant treatment showed that no significant differ-
ence exists between the groups (p = 0.783): (4 (10.5%) vs 37 (6.8%) had chemotherapy, 9
(23.7%) vs 99 (18.1%) had combined radio-chemotherapy, and 3 (7.9%) vs 89 (16.1%) had
radiation alone (brachytherapy and/or pelvic radiotherapy); one patient in the POLE non-
mutated group had hormonal treatment.
Subgroup analysis included endometrioid tumours (n = 465, POLE mutations in 30 cases)
and Grade 3 endometrioid tumours (n = 72, POLE mutations in 10 cases). No recurrence was
noted in the endometrioid group with POLE mutation; however, in the Cox-regression analy-
sis for risk of recurrence, no significance was reached (p = 0.172; CI 0.001–3.884). In addition,
analysis of the non-endometrioid tumours (N = 98) showed that the POLE mutation (N = 7)
did not have a significant positive effect on survival.
In a further subgroup analysis of the effect of POLE mutation on outcome in EMCA, we
performed Cox regression analysis on ESMO risk groups applied to our cohort [24]. Within
each risk group, no significant difference could be seen as to whether or not a POLE mutation
was present.
Discussion
This study presents the phenotypic and mutational spectrum of a large cohort of POLE-
mutated tumours. By combining extensive clinical data, including detailed information on life-
style, POLE mutations, and survival outcome, this work identifies a few distinct phenotypic
characteristics of women with POLE-mutated EMCA. First, women with POLE-mutated
tumours are younger. Previous studies, including Bosse et al., already also showed a trend
towards a lower age [10]. Differences in age of onset may be related to differences in cancer
development. Indeed, the mean age of the diagnosis of simple hyperplasia is 50–54 and the
mean age of the diagnosis of atypical hyperplasia is 60–64 [25]. In our cohort, the mean age of
POLE-mutated tumours was 60.1 years versus 66.5 years in non-POLE mutated tumours. The
existence of a POLE mutation makes a tumour susceptible to acquiring additional mutations
and may accelerate the transition from precancerous lesion to cancer. The fully developed ade-
nocarcinoma, however, may then be kept under control by high neoantigen loads and number
of tumour-infiltrating lymphocytes, thus inducing a local immune response and explaining
Phenotype of POLE-mutated endometrial cancer
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the good outcome [16,18,26]. A high BMI is known to be a risk factor for EMCA, favouring
the usual type I EMCA [27]. Therefore, these findings might suggest a different pathogenic
pathway than in the case of a typical type I EMCA.
In addition to the age factor and the trend towards lower BMI, patients with POLE-mutated
tumours are more often current or former smokers. A recently published large study of the
risk of smoking for cancer as well as a meta-analysis published in 2008 suggest that smoking
may reduce the general risk of developing EMCA [28–30]. However, in premenopausal
women, smoking was a secondary risk factor for developing EMCA in 5 out of 9 studies sum-
marized in a meta-analysis published in 2016 [27]. Therefore, the identification of more POLE
tumours in ever-smokers is intriguing. Smoking appears to cause mutations via direct action
of carcinogens in smoke and smoke metabolites on DNA, but also via additional pathways,
such as defects in DNA repair, as in the case of occasional POLE mutations [31]. A recent arti-
cle demonstrates that clustered mutation signatures, combined with error-prone DNA repair,
leads to accumulation of mutations in active, more important regions of the genome [32]. The
degree to which these processes are active in EMCA needs to be evaluated in future studies.
Another interesting and important finding from the analysis of the histopathology of the
tumours is that there is no significant difference between the histologic type or stage of the
POLE-mutated versus the non-POLE tumours. In our cohort, POLE-mutated tumours do pro-
ceed to lymph-node metastasis and may also be non-endometrioid. In the sub-analysis of
endometrioid grade 3 tumours (N = 72), there are significant differences in prevalence
between the groups (23.7% vs 11.2% p = 0.022). This confirms the results from the other pub-
lished large cohorts showing that POLE mutated tumours are more often endometrioid and
high grade [10,14,33,34]. This finding is not new, but is an important confirmation, since sev-
eral of these cohorts have had differences in the inclusion criteria. For example, the PORTEC
studies included primarily intermediate to intermediate-high risk cases and the TCGA
included primarily high-risk cases. The KImBer cohort represents a population with EMCA
without pre-selection, therefore very representative of the general population.
From the KS cohort, information on ploidy shows that POLE-mutated tumours are signifi-
cantly more often aneuploid than non-POLE-mutated tumours. Ploidy alone is known as a
risk factor for more aggressive tumour biology. Furthermore, in these 331 patients, progres-
sion-free survival was significantly worse in the aneuploid group (log rank 0.000); this finding
is consistent with the findings of other large studies on ploidy in EMCA [35]. Importantly, the
role of ploidy is subtype specific. The POLE-mutated tumours were significantly more often
aneuploid, but there was no difference in outcome between aneuploid and diploid tumours
within the POLE-mutated group. This finding within a larger cohort confirms the results by
Hoang et al, who examined the ploidy of different molecular subgroups; they also found that
within the total cohort, aneuploid tumours had a worse outcome, but that within the POLE
tumours there was no difference in PFS [36]. Usually, non-diploid cells are a sign of genomic
instability, which is in general a risk for more aggressive tumour biology. The genomic insta-
bility in the POLE-mutated tumours is not due to aneuploidy but rather to the missing con-
trols in DNA replication and therefore reflects a different mechanism; this may be the reason
for the missing effect of ploidy on prognostic significance [37].
In analysis of the PFS and DSS, the hotspot POLE-mutated tumours do have a significantly
better outcome; this finding confirms previously published data that POLE mutated tumours
have a good outcome. Cohorts have been published from Vancouver, subgroups of PORTEC-
1 and 2, the TCGA, Ohio, Calgary, Singapore, and combined PORTEC-NGO, presenting a
total of over 150 POLE-mutated tumours with good to excellent survival rates [10,16,19,34,38–
40]. Note, however, that many of these studies have included a range of POLE mutations in
the “POLE mutated” group (summarized in Table 4)
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Sequencing of exons 9–14 of the POLE gene, as performed in this study, but also performed
in numerous previous studies, has led to the identification of numerous non-synonymous
mutations (summarized in Table 3). Interpretation of these mutations, and determination of
their being “pathogenic” or not, is a growing issue that has been handled differently by differ-
ent authors (Table 4). The relationship between a particular mutation and the clinical pheno-
type of “good prognosis” is not entirely clear. In this study, we defined a “POLE-mutated
tumour” using a restrictive definition that included only five previously described hotspot
mutations (P286R, V411L, S297F, A456P and S459F). Using this definition, POLE-mutated
tumours showed the phenotypic findings we have described above. We also identified tumours
with mutations that have been demonstrated to lead to a high TMB. A subgroup analysis
including these in a “POLE-mutated” group also demonstrated a good prognosis. However,
we found a large range of additional mutations where the significance is not clear and can pose
difficulty in interpreting the results. By adding all the POLE mutations to the analysis, the out-
come is not significantly better compared to no POLE mutation (Kaplan Meier curves pre-
sented in S2 File). Some of these mutations have been designated as “pathogenic” by other
authors and tumours have been included in “POLE-mutated” groups based on them (see
Table 4). This analysis shows that a correct selection of pathogenic mutations influences the
results significantly and means that previous papers that have included mutations of unclear
significance should perhaps be revisited. Our results suggest that the safe definition of POLE-
mutated EMCA with prediction of an excellent outcome should, for the moment, be restricted
to endometrioid EMCA with the five hotspot mutations we have listed, with perhaps the inclu-
sion of the high TMB mutations. We would argue that no other mutations should be included
in this group until their biology is more completely understood.
As seen in the work of Framton et al., in analysing a large number of somatic mutated
tumours, the variance of the TMB is large and therefore shows that mutation alone does not
have to result in a high TMB [4]. In addition to the characteristic of a high mutation rate, the
POLE-mutated tumours as classified by the TCGA have specific nucleotide missense muta-
tions such as TCT!TAT and TCG!TTG mutations [5,19]. Clearly, more research is needed
Table 4. Mutations defined as pathogenic in previous cohorts.
Publication Nr of POLE
mutated
tumors
Sequencing method Mutations included in the
“POLE mutated” group
Definition of pathogenic mutation
Tomlinson et al 2013 14 Sanger sequencing (codons
268–471)
P286R, S297P, V411L, A456P,
A275V
Predictive and functional analysis
McAlpine et al 2015 39 Sanger sequencing exons 9 to
14
P286R, S297P, V411L, A456P,
M295R, F367S/C, P436R, L424P,
P441L, F367L, E396G
Ngeow et al 2016 12 Nextgeneration sequencing
and sanger sequencing to
confirm
P286R, V411L, A456P, S459F
A465F, M444K, S459P
In silico testing of mutations to define pathogenity
Billingsley et al 2015
and Goodfellow et al
2017
40/39 Sanger sequencing (residues
268–471)
P286R, S297P, V411L, A456P,
P436R, A465F, A426V
assessed using mutation assessment prediction programs
Bosse et al 2015 63 Sanger sequencing exon 9
and 13 (PORTEC)
P286R, S297P, V411L, M299V,
S297T
defined as pathogenic POLE proofreading mutations as
variants absent from public germline sequence databases
and previously confirmed as somatic variants associated
with tumor ultramutation
Ko¨bel et al 2014 8 Sanger sequencing exon 9–13 P286R, V411L, T278M, S297P all mutation positive samples
References [10,40–44]
https://doi.org/10.1371/journal.pone.0214318.t004
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to understand which POLE mutations lead to a phenotype with better clinical outcome and
whether this is due to the POLE mutation alone leading to an ultramutation or to another
mutation within the many mutations further down the road, leading to the good outcome.
In the KS cohort, no mutations were found in exons 10 and 11. This supports the recent lit-
erature [44], so it is probable that the sequencing of exons 9, 12, 13, and 14 is sufficient but also
necessary for diagnosing pathogenic POLE mutations.
One limitation of this study is the lack of additional molecular characterization. Several
studies have indicated that POLE-wildtype EMCA can have deficiencies in other molecular
pathways, such as mismatch repair, and can even be p53 mutated. While the original TCGA
paper and the ProMisE classifier include tumours with multiple classifiers (and have demon-
strated the POLE group as having a distinctly favourable prognosis), other groups, notably the
papers focusing on the PORTEC cohort, have excluded cases with multiple classifiers
[10,45,46]. This question needs to be addressed in future studies.
Conclusions
In this large representative cohort, patients with POLE-mutated EMCA are younger, more
often nulliparous, and more often current or prior smokers. POLE mutations do lead to a bet-
ter outcome; however, a careful definition of pathogenic POLE mutation is needed. Subgroup
analysis of identified POLE mutations demonstrate that a restrictive definition of “POLE-
mutated EMCA” is necessary to achieve the reported good survival, as including variants of
uncertain significance leads to inclusion of cases with worse prognosis. Possibly, the identifica-
tion of more factors, such as additional mutations or total mutational burden, might be needed
to identify clearly pathogenic POLE mutations with the associated excellent prognosis. These
results show that finding a POLE mutation alone has limits in identifying a clear clinical cohort
and more research is needed to better understand the mechanisms of the different POLE
mutations. In anticipating of the use of checkpoint inhibitors for ultramutated tumours, this
molecular marker may evolve to be an important factor in treatment for EMCA, especially in
patients with advanced or recurrent disease.
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